Robert Bhatt

Robert Bhatt has contributed to clinical investigation of IO plus chemotherapy combinations for gastric and gastroesophageal junction cancers, where first-line checkpoint inhibitor integration has significantly improved outcomes for patients with PD-L1-positive disease. His research has examined the CheckMate 649 trial establishing nivolumab plus chemotherapy as a first-line standard for gastric/GEJ adenocarcinoma with CPS >=5 or >=1, and analyzed biomarkers predicting magnitude of benefit including PD-L1 CPS, TMB, and immune gene expression profiles. He has studied the emerging combination data with trastuzumab for HER2-positive gastric cancer incorporating checkpoint inhibitors, examining the triplet of anti-HER2, immunotherapy, and chemotherapy from KEYNOTE-811. His translational work connects tumor immune microenvironment characterization in gastric cancer with IO combination therapy outcomes.